Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Labcorp (NYSE: LH) has achieved IVDR CE-marking for its PGDx elio tissue complete test in the European Union, making it the first and only test of its kind approved for comprehensive solid tumor profiling under new EU regulations. The test, which already has FDA clearance in the US, will help diagnose and treat approximately 2.7 million people diagnosed with cancer annually in the EU.
The in vitro diagnostic assay can analyze multiple biomarkers simultaneously, even with limited tissue samples, enabling faster and more effective patient management plans. The test will be available through Labcorp's central laboratory in Geneva, Switzerland, supporting both biopharma partners and investigational use in global clinical trials.
Labcorp (NYSE: LH) reported strong Q2 2025 results with revenue of $3.53 billion, up 9.5% from Q2 2024. The company achieved diluted EPS of $2.84 and adjusted EPS of $4.35, marking a 10.4% increase year-over-year.
Based on strong performance, Labcorp raised its full-year 2025 guidance, with revenue growth now expected at 7.5% to 8.6%, adjusted EPS range of $16.05 to $16.50, and free cash flow projected between $1.13-$1.28 billion. The company expanded through strategic acquisitions, including assets from Incyte Diagnostics and BioReference Health, while launching innovative oncology tests and expanding its consumer offerings.
The company maintained its shareholder returns with a $0.72 quarterly dividend and $200 million in share repurchases during Q2.
Community Health Systems (NYSE:CYH) has entered into a definitive agreement to sell select ambulatory outreach laboratory assets to Labcorp (NYSE:LH) for $195 million in cash. The transaction covers laboratory services across 13 states, including patient service centers and in-office phlebotomy locations.
CHS will retain operation of inpatient and emergency department laboratories while continuing to provide hospital-based laboratory services. The deal aims to provide broader access to Labcorp's comprehensive testing services, specialty testing menu, data analytics, and digital tools. The transaction is expected to close in Q4 2025, subject to regulatory approvals.
Labcorp (NYSE:LH), a leading global laboratory services provider, has announced a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on September 11, 2025, to shareholders of record as of August 28, 2025.
Labcorp (NYSE:LH), a leading provider of innovative laboratory services, has scheduled its Q2 2025 financial results announcement for July 24, 2025, before market opening. The company will host a conference call and webcast at 9:00 AM ET to discuss the results.
Investors can access the earnings release and financial information on Labcorp's Investor Relations website. A webcast replay will be available approximately two hours after the event until July 11, 2026.
SOLVD Health has strengthened its Board of Directors with the appointments of Mike Aicher and Vince Cebula. Aicher, a diagnostics pioneer with over 30 years of executive experience, co-founded National Genetics Institute (acquired by Labcorp) and previously led Labcorp's Esoteric Business Units, generating over $1 billion in annual revenue. Cebula brings extensive financial expertise from roles at Oaktree Capital Management and Jefferies Capital Partners.
These strategic appointments come as SOLVD Health advances its proprietary diagnostics platform, including the FDA-approved AvertD® test for assessing genetic risk of opioid use disorder (OUD). The company aims to expand its personalized health solutions and precision diagnostics platform to deliver better health outcomes through data-driven innovation.
Labcorp (NYSE: LH), a leading global laboratory services provider, has announced that its Annual Meeting of Shareholders will be held virtually on May 15 at 9:00 a.m. ET. Shareholders and interested parties can access the live webcast through the company's Investor Relations website. The recorded session will remain available for replay for one year following the meeting.
Labcorp reported strong Q1 2025 financial results with total revenue reaching $3.35 billion, up 5.3% from $3.18 billion in Q1 2024. The company's adjusted EPS increased to $3.84 from $3.68, while diluted EPS decreased to $2.52 from $2.69.
Key developments include:
- Launch of Labcorp Plasma Complete, a new liquid biopsy test for cancer treatment
- Introduction of pTau-217/Beta Amyloid 42 Ratio test for Alzheimer's diagnosis
- Strategic collaboration with Inspira Health for hospital laboratory management
- Acquisition of BioReference Health's oncology testing assets
The company updated its 2025 guidance, maintaining revenue growth projections of 6.7% to 8.0% and raising the midpoint of adjusted EPS to $15.70-$16.40. Free cash flow is expected between $1.10-$1.25 billion. Labcorp also announced a quarterly dividend of $0.72 per share, payable June 11, 2025.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
